Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.46 |
| ▸ | CSF1R | P07333 | 2/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.33 |
| ▸ | CDK1 | P06493 | 2/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.33 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14779031 | 1.00 | TSHR (0.61) | TSHRRECQLCYP1A2CDK2NUDT1 | |
| SCHEMBL14779334 | 0.89 | CDK2 (0.59) | TSHRRECQLCYP1A2CDK2NUDT1 | |
| SCHEMBL14779029 | 0.84 | TSHR (0.53) | TSHRRECQLCYP1A2CDK2NUDT1 | |
| SCHEMBL14779867 | 0.83 | TSHR (0.64) | TSHRRECQLCYP1A2CDK2NUDT1 | |
| SCHEMBL14779864 | 0.83 | TSHR (0.64) | TSHRRECQLCYP1A2CDK2NUDT1 | |
| SCHEMBL14786534 | 0.77 | NUDT1 (0.47) | TSHRRECQLNUDT1 | |
| SCHEMBL14786537 | 0.77 | NUDT1 (0.47) | TSHRRECQLNUDT1 | |
| SCHEMBL25176316 | 0.76 | TSHR (1.00) | TSHRRECQLCYP1A2CDK2CYP3A4 | |
| SCHEMBL49690 | 0.76 | TSHR (1.00) | TSHRRECQLCYP1A2CDK2CYP3A4 | |
| SCHEMBL29412055 | 0.76 | TSHR (1.00) | TSHRRECQLCYP1A2CDK2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2755977-B1 | 6,8-DISUBSTITUTED PURINE COMPOSITIONS AND THEIR PHARMACEUTICAL AND COSMETIC USE | Univerzita Palackého v Olomouci (CZ) | 2016-11-02 | — | — | EP | disclosed |
| US-20130072506-A1 | 6,8-DISUBSTITUTED PURINE COMPOSITIONS | ZAHAJSKA LENKA (CZ) | 2013-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072506-A1 | 6,8-DISUBSTITUTED PURINE COMPOSITIONS | UNG, PNP, UMPS | TSHR 3236/4885RECQL 640/4885CYP1A2 1398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.